[PDF] The Oncogenomics Handbook eBook

Author : William J. LaRochelle
Publisher : Springer Science & Business Media
Page : 745 pages
File Size : 17,28 MB
Release : 2007-11-09
Category : Medical
ISBN : 1592598935

GET BOOK

An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.

Author : Zena Murray
Publisher : American Medical Publishers
Page : 229 pages
File Size : 50,5 MB
Release : 2021-11-16
Category : Medical
ISBN : 9781639272518

GET BOOK

The accumulation of DNA mutations and epigenetic variations that leads to uncontrolled cell proliferation and formation of neoplasm refers to cancer. It is a genetic disease. The sub branch of genomics that deals with the study of cancer related genes is known as oncogenomics. The primary goal of the discipline is to recognize new tumor suppressor genes and oncogenes that may lead to new insights in the diagnosis of cancer, help predict the clinical outcome of different cancers and identify new targets for cancer therapies. It uses the techniques of transciptomes, genome sequencing, bioinformatics, functional analysis of oncogenes, etc. The field is also concerned with personalizing cancer treatment by identifying and targeting mutations in an individual patient. The book elucidates the concepts and innovative models around the prospective developments with respect to oncogenomics. The various studies that are constantly contributing towards advancing technologies and evolution of this field are examined in detail. This book, with its detailed analyses and data, will prove immensely beneficial to professionals and students involved in this area at various levels.

Author : Charles Brenner
Publisher : John Wiley & Sons
Page : 411 pages
File Size : 11,30 MB
Release : 2004-11-19
Category : Medical
ISBN : 0471476641

GET BOOK

This book aims to assemble the only available rigorous, yet broadly accessible introduction to this new and exciting field. Oncogenomics: Molecular Approaches to Cancer is approachable by basic scientists, practitioners, and other health professionals required to familiarize themselves with the tremendous impact of genomics and proteomics on cancer research. Clearly written chapters offer reviews of state of the art topics such as molecular classification, early detection, SNPs in cancer, data mining, tissue microarrays, protein and antibody arrays, and drug targets.

Author : Franco Dammacco
Publisher : Academic Press
Page : 718 pages
File Size : 43,62 MB
Release : 2018-10-30
Category : Medical
ISBN : 0128117869

GET BOOK

Oncogenomics: From Basic Research to Precision Medicine offers a thorough survey of precision medicine and its diagnostic and therapeutic applications in oncology. Gathering contributions from leading international researchers in the field, chapters examine recent translational advances in oncogenomic methods and technologies, detailing novel molecular classifications of tumors as well as diagnostic and prognostic biomarkers for various types of cancers including pancreatic, gastrointestinal, breast, hematological, lung, osteotropic, genitourinary, and skin cancers. This book provides a foundation for clinical oncologists, human geneticists, and physicians to develop new targeted cancer treatments and incorporate genomic medicine into clinical practice, with particular attention paid to noninvasive diagnostic techniques such as the liquid biopsy and molecular characterization of solid malignancies. Provides clinical oncologists, human geneticists, physicians, and students with a thorough understanding of current diagnostic and prognostic applications of genomic methods and technologies to a variety of solid malignancies Employs current knowledge in oncogenomics towards developing therapeutic interventions for various cancer types Features a team of internationally recognized researchers and physicians in clinical oncology, oncogenomics and precision medicine

Author : Malcolm Alison
Publisher : Nature Publishing Group
Page : 928 pages
File Size : 13,47 MB
Release : 2002
Category : Medical
ISBN :

GET BOOK

Provides a comprehensive overview of all major areas of cancer research and oncology. Bridging the gap between the molecular biology of cancer and clinical diagnosis and treatment, this online reference work provides a resource for medical and life sciences students, as well as all scientists, clinicians and researchers working in the cancer field and related biomedical areas.

Author : Gurmit Singh
Publisher : Springer Science & Business Media
Page : 343 pages
File Size : 33,76 MB
Release : 2007-10-28
Category : Medical
ISBN : 1592598927

GET BOOK

A state-of-the-art review of the molecular underpinnings of bone-seeking cancers, current treatment approaches for them, and future therapeutic strategies. The authors illuminate the role of various autocrine, paracrine, and immunological factors involved in the progression and establishment of bone metastases, highlighting the physiological processes that lead to bone degradation, pain, angiogenesis, and dysregulation of bone turnover. They also discuss the various strategies that appear to have promise and are currently deployed in treatment or are at the experimental stage.

Author : Doriano Fabbro
Publisher : Springer Science & Business Media
Page : 599 pages
File Size : 27,91 MB
Release : 2007-11-13
Category : Science
ISBN : 1592599621

GET BOOK

Leading researchers, from the Novartis group that pioneered Gleevec/GlivecTM and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.

Author : Beverly A. Teicher
Publisher : Springer Science & Business Media
Page : 611 pages
File Size : 13,11 MB
Release : 2007-11-09
Category : Medical
ISBN : 1597450359

GET BOOK

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.

Author : Mary L. Disis
Publisher : Springer Science & Business Media
Page : 517 pages
File Size : 25,30 MB
Release : 2007-10-28
Category : Medical
ISBN : 1597450111

GET BOOK

Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined.

Author : Beverly A. Teicher
Publisher : Springer Science & Business Media
Page : 585 pages
File Size : 12,52 MB
Release : 2008-01-08
Category : Medical
ISBN : 1597451843

GET BOOK

This volume represents a compendium of scientific findings and approaches to the study of angiogenesis in cancer. The second edition of Antiangiogenic Agents in Cancer Therapy is intended to give a current perspective on the state-of-the-art of angiogenensis and therapy directed at this process. Antiangiogenesis is a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge.